|Day Low/High||0.00 / 0.00|
|52 Wk Low/High||4.60 / 8.63|
Significant correlation between overall tumor biomarker response and achievement of the primary and secondary endpoints in pivotal study of AZEDRA
Investors eyeing a purchase of Progenics Pharmaceuticals, Inc. stock, but cautious about paying the going market price of $8.39/share, might benefit from considering selling puts among the alternative strategies at their disposal.
These names are showing technical characteristics of either bullish or bearish reversal patterns over the past week.
Investors in Progenics Pharmaceuticals, Inc. saw new options become available this week, for the April 20th expiration.
Here are a few key events I will be watching closely for in the months ahead on stocks I think are buys at current levels.
A roundup of biotech names with actions pending at the FDA in coming weeks.
I've added to my positions in these names on yesterday's intraday silliness.
Top-line Data Expected in 3Q2018
Investors in Progenics Pharmaceuticals, Inc. saw new options become available this week, for the August 2018 expiration.
Sector M&A activity is likely to pick up next year benefiting the space.
We are coming my favorite part of earnings season -- when these small-caps report.
The housing market will continue to improve over the next few years due to pent up demand.
Eagle Pharmaceuticals, Aratana Therapeutics and Progenics Pharmaceuticals show promise.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.